Dare Bioscience Inc (DARE) Stock Price, Quote & News

Company Profile

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual aro...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 926 7655

Website: darebioscience.com

Address:

3655 Nobel Drive, Suite 260, San Diego, United States

BuyAndHoldStocks Mar. 15 at 6:58 PM

$DARE If Organon is investing in TikTok marketing for Xaciato, they clearly expect a return — this has likely been part of the launch strategy from the start. https://itsdovi.com/#/organon-xaciato/ Stronger sales acceleration could potentially trigger milestone payments. XOMA (Daré) is eligible for up to $182.5M in milestones plus tiered double-digit royalties on net sales. 💰 Xaciato also has QIDP status from the U.S. Food and Drug Administration, which provides extended market exclusivity in the U.S. On top of that, Organon has partnered with Evvy. Women diagnosed with bacterial vaginosis via Evvy’s at-home test can get a prescription for Xaciato directly through the platform — potentially enabling same-day treatment without a clinic visit.

0 · Reply

BuyAndHoldStocks Mar. 15 at 2:04 PM

$DARE Daré received $22M in gross proceeds at closing. After XOMA achieves a pre-specified total return, Daré will receive milestone payments equal to 50% of all remaining cash flows sold to XOMA under the agreement. As of Q3 2025, XOMA had received about $0.5M from the asset. I don’t expect XACIATO to materially impact Daré in the near term, but if the commercial ramp accelerates in 2026, it could become meaningful for Daré by 2027. The market opportunity is substantial. Bacterial vaginosis (BV) affects roughly 21 million women, and the symptoms are often mistaken for a yeast infection, suggesting significant underdiagnosis and treatment potential. XOMA reports earnings on March 18, which should provide a clearer picture of the current growth trajectory.

0 · Reply

BuyAndHoldStocks Mar. 15 at 1:46 PM

$DARE ”Once biological differences become measurable, they become actionable. By bringing modern microbiome science into BV care, this research lays the groundwork for more precise studies, more effective treatments, and ultimately better reproductive health outcomes.” https://www.evvy.com/blog/bv-subtypes-research

0 · Reply

BuyAndHoldStocks Mar. 15 at 1:43 PM

$DARE ”Advancing biological resolution in BV care reflects a broader commitment to bringing precision medicine into women’s health at scale. For the millions affected each year, a deeper understanding offers a path toward more predictable care, longer-lasting relief, and stronger reproductive confidence.” https://www.evvy.com/blog/bv-microbial-diversity-subtypes-research

0 · Reply

BuyAndHoldStocks Mar. 15 at 1:31 PM

$DARE 💡 By integrating testing, diagnosis, and prescription into a digital care pathway, the partnership meaningfully lowers barriers to treatment and could accelerate adoption. As Evvy’s user base continues to grow, the platform has the potential to become a powerful commercial channel, positioning XACIATO for a significant sales ramp in 2026 and beyond. 🚀📈 https://www.futurefemhealth.com/p/organon-and-evvy-team-up-to-broaden

0 · Reply

BuyAndHoldStocks Mar. 15 at 1:30 PM

$DARE 💡💡2026 could mark the inflection point for XACIATO’s commercial ramp. Through its partnership with Evvy, the product is gaining access to one of the fastest-growing platforms in vaginal microbiome testing and digital women’s health. Evvy reported more than 75,000 patients and 2,000 healthcare providers on its platform as of October 2025, and further expanded its ecosystem with the launch of an at-home clinical care program in December 2025. https://www.evvy.com/blog/why-how-we-built-clinical-care-with-evvy The collaboration enables women diagnosed with bacterial vaginosis through Evvy’s at-home testing to obtain prescriptions for XACIATO—a single-dose treatment developed by Organon—directly through the platform. This streamlined model allows for potential same-day diagnosis and treatment without requiring an in-person clinic visit. https://wewillcure.com/insights/company-profiles/womens-health-startups-to-watch-in-2026

0 · Reply

BuyAndHoldStocks Mar. 15 at 11:41 AM

$DARE The session closed with a record-low trading volume of only 53 shares, indicating that market liquidity is effectively nonexistent. This creates an asymmetric risk profile for short sellers. 💀 As liquidity tightens, attempts to cover positions can themselves generate incremental demand and signal strengthening market interest. Rather than facilitating orderly exits, covering activity may contribute to upward price pressure and reinforce positive price momentum. In extreme cases, this dynamic can evolve into a reflexive feedback loop in which limited supply, rising prices, and short covering interact to accelerate

0 · Reply

BuyAndHoldStocks Mar. 15 at 9:14 AM

$DARE Additional publicity in Women’s World highlights the potential of sildenafil cream for women. Considering Dare’s active presence at multiple conferences, it is reasonable to assume that awareness among physicians is increasing and that prescriptions may already be starting. See Dare’s Instagram for examples of how they have actively promoted Dare to Play. https://www.womansworld.com/wellness/how-scream-cream-is-boosting-arousal-for-women-over-50 💡 Women Are Buzzing About ‘Scream Cream’—Doctors Say It May Boost Arousal Fast

0 · Reply

BuyAndHoldStocks Mar. 15 at 7:55 AM

$DARE When a concentrated base of long-term investors continues to accumulate shares while maintaining low willingness to lend or sell, the effective tradable float can compress materially. ☠️☠️☠️Under these conditions, short sellers face increasing liquidity risk. Efforts to cover positions introduce incremental demand into an already supply-constrained market, potentially amplifying price appreciation and reinforcing bullish momentum.

0 · Reply

Shortystopper Mar. 15 at 4:44 AM

$DARE 25k watchers, 1 pumper = Dead

0 · Reply

Daré Bioscience Participates in Virtual Investor “What This Means” Segment

Feb 23, 2026, 8:00 AM EST - 20 days ago

Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

Dec 10, 2025, 8:00 AM EST - 3 months ago

DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility

Nov 22, 2025, 7:23 AM EST - 4 months ago

Daré Bioscience, Inc. (DARE) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns Transcript

Nov 13, 2025, 7:41 PM EST - 4 months ago

Daré Bioscience, Inc. (DARE) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 4:01 PM EST - 4 months ago

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 6, 2025, 8:00 AM EST - 4 months ago

Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

Sep 24, 2025, 8:00 AM EDT - 6 months ago

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

Aug 14, 2025, 7:48 PM EDT - 7 months ago

Daré Bioscience, Inc. (DARE) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 4:01 PM EDT - 7 months ago

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 8:00 AM EDT - 7 months ago

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

Jul 29, 2025, 8:00 AM EDT - 8 months ago

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

Jul 21, 2025, 1:47 PM EDT - 8 months ago

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Jul 14, 2025, 1:09 PM EDT - 8 months ago

Crude Oil Moves Lower; Daré Bioscience Shares Jump

Jul 14, 2025, 8:00 AM EDT - 8 months ago

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Jul 11, 2025, 8:00 AM EDT - 8 months ago

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Jun 12, 2025, 5:00 PM EDT - 9 months ago

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

May 13, 2025, 11:13 PM EDT - 10 months ago

Daré Bioscience, Inc. (DARE) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:01 PM EDT - 10 months ago

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

Mar 31, 2025, 10:14 PM EDT - 1 year ago

Daré Bioscience, Inc. (DARE) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Feb 6, 2025, 8:00 AM EST - 1 year ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

Jan 9, 2025, 8:00 AM EST - 1 year ago

Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 14, 2024, 8:03 PM EST - 1 year ago

Daré Bioscience, Inc. (DARE) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 4:01 PM EST - 1 year ago

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Nov 7, 2024, 8:00 AM EST - 1 year ago

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Oct 23, 2024, 12:30 PM EDT - 1 year ago

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

Oct 21, 2024, 8:05 AM EDT - 1 year ago

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

Aug 12, 2024, 8:40 PM EDT - 1 year ago

Daré Bioscience, Inc. (DARE) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

Jul 19, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Jul 1, 2024, 6:54 AM EDT - 1 year ago

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

KPRX

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Announces Reverse Stock Split

May 14, 2024, 6:30 PM EDT - 1 year ago

Daré Bioscience, Inc. (DARE) Q1 2024 Earnings Call Transcript

May 14, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

May 2, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

Apr 30, 2024, 7:30 AM EDT - 2 years ago

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Mar 28, 2024, 8:47 PM EDT - 2 years ago

Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

Mar 15, 2024, 2:33 PM EDT - 2 years ago

This overlooked corner of women's health could be a $350 billion market opportunity

PFE PGNY VTGN BTMD

Jan 31, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Jan 26, 2024, 4:30 PM EST - 2 years ago

Daré Bioscience Announces Executive Team and Board of Directors Changes

Jan 17, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Jan 4, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases

Dec 26, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Dec 20, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

BuyAndHoldStocks Mar. 15 at 6:58 PM

0 · Reply

BuyAndHoldStocks Mar. 15 at 2:04 PM

0 · Reply

BuyAndHoldStocks Mar. 15 at 1:46 PM

0 · Reply

BuyAndHoldStocks Mar. 15 at 1:43 PM

0 · Reply

BuyAndHoldStocks Mar. 15 at 1:31 PM

0 · Reply

BuyAndHoldStocks Mar. 15 at 1:30 PM

0 · Reply

BuyAndHoldStocks Mar. 15 at 11:41 AM

0 · Reply

BuyAndHoldStocks Mar. 15 at 9:14 AM

0 · Reply

BuyAndHoldStocks Mar. 15 at 7:55 AM

0 · Reply

Shortystopper Mar. 15 at 4:44 AM

$DARE 25k watchers, 1 pumper = Dead

0 · Reply

BuyAndHoldStocks Mar. 14 at 5:57 PM

$DARE 💡👀💡👀💡👀💡👀💡👀💡

0 · Reply

BuyAndHoldStocks Mar. 14 at 5:29 PM

$DARE ARPA-H Awards: The Quiet Signal for Women’s Health Biotech Exits 🚀 Look at Celmatix: • 2024: $3.5M ARPA-H “Sprint for Women’s Health” award • 2026: Acquired by Gedeon Richter for its fertility and endometriosis programs Pattern: government grant → proof-of-concept → strategic pharma acquisition. Non-dilutive funding turned into real exit value in <2 years. Now, Daré Bioscience is following a similar path: • $10M ARPA-H award • FDA recently cleared an IND for one of its lead programs ✅ Catalysts are stacking: ARPA-H validation + FDA IND clearance = early signal of strategic relevance. History (Celmatix) shows this can lead to acquisitions by pharma looking to expand women’s health pipelines. If you’re tracking women’s health biotech, Daré could be next in line for a fast-moving exit story. Women’s health innovation is finally getting serious backing — ARPA-H might be the early signal every investor should watch. 👀💡

1 · Reply

BuyAndHoldStocks Mar. 14 at 4:13 PM

$DARE 💡🎯💡📈🕛 9/ The overlooked point for investors: ARPA-H support provides non-dilutive funding, scientific validation, and commercialization infrastructure—all of which significantly de-risk development. 10/ For a small biotech, that combination—government validation + funding + commercialization support—can meaningfully improve the probability of bringing a new therapy to market.

0 · Reply

BuyAndHoldStocks Mar. 14 at 3:59 PM

$DARE 💡👀💡Why the ARPA-H LaunchPad award for Daré Bioscience may be more important than the market currently realizes. 1/ Daré was selected by ARPA-H’s LaunchPad program and can receive up to $10M in milestone-based, non-dilutive funding to advance DARE-HPV. LaunchPad is designed for technologies approaching commercialization—not early-stage academic research. 2/ ARPA-H is modeled after DARPA and is highly selective. Being chosen signals that the U.S. government sees both significant clinical impact and real-world deployment potential. 3/ The support goes beyond funding. Daré also receives commercialization guidance through the LaunchPad Accelerator and collaboration with an Entrepreneur-in-Residence focused on bringing the technology to market. https://arpa-h.gov/explore-funding/initiatives-and-sprints/sprint-for-womens-health

1 · Reply

BuyAndHoldStocks Mar. 13 at 4:54 PM

$DARE One tactic sometimes discussed in market analysis is the possibility that certain participants attempt to influence short-term price movements by trading volume between affiliated accounts or through separate brokerage accounts. While such practices would be considered market manipulation and therefore illegal, they can be difficult to identify in real time without regulatory investigation, for example by the SEC. The intended effect of this type of activity would typically be to create artificial selling pressure in order to trigger stop-loss orders and force weaker retail positions out of the market. Based on today’s trading data, approximately 71% of the volume appears to originate from retail activity, while around 29% is attributed to dark pool transactions. This distribution suggests that the current selling pressure is more likely driven by retail participants rather than by market makers.

0 · Reply

BuyAndHoldStocks Mar. 13 at 4:05 PM

$DARE Short sellers and retail traders often try to make you give up and believe there is no bottom. But even in Dare, the stock has surged twice in the past year, and there is nothing to suggest it couldn’t happen again. ⏳ 💡Patience, combined with a deep understanding of what you own, helps you recognize the value of your investment. Continue accumulating over time. The trading volume also indicates that liquidity is largely limited.☠️

0 · Reply

BuyAndHoldStocks Mar. 13 at 2:08 PM

$DARE 💡👀💡

1 · Reply

BuyAndHoldStocks Mar. 13 at 12:40 PM

$DARE 💡 SI has been trending lower while borrow remains relatively benign, suggesting the persistent downside pressure is unlikely to be driven by incremental short positioning. The flow instead appears more consistent with retail supply from larger holders leaning on the tape, potentially with the intent to re-accumulate at lower levels. Similar dynamics have been observed in prior trading periods.

0 · Reply

BuyAndHoldStocks Mar. 12 at 6:16 PM

$DARE 💡One tip is not to defend any levels, let those who want to sell you cheaper. Believe in your investment and accumulate continuously. The trend may look boring, but you are investing for reasons that can provide significant returns. None of us have a date when the stock can jump up, those who buy first at the next big event are those who have previously shorted.

0 · Reply

BuyAndHoldStocks Mar. 12 at 5:50 PM

$DARE Don't look at individual prints on a few hundred shares, instead judge the situation based on where volume has been traded. If your goal is to buy 100 - 2000 shares, prints at low levels can of course be significant, but not if you want volume. Summary of the latest technical analysis for Daré Bioscience (DARE) based on VWAP and volume profile: 1️⃣ Current Price Context • Current price: ~$1.50 • 30-day VWAP: ~$1.84–$1.88 • Anchored VWAP from December 2025 high ($2.47): ~$2.30 • Anchored VWAP from January capitulation low (~$1.78): ~$1.78 Interpretation: • The stock is trading well below all VWAP levels, indicating a bearish short-term structure. • Anchored VWAP from the capitulation low coincides with a key support/accumulation area.

1 · Reply

BuyAndHoldStocks Mar. 12 at 4:44 PM

$DARE I accumulate every week.💡🕛⏳

0 · Reply

BuyAndHoldStocks Mar. 12 at 4:37 PM

$DARE Let the short sell to you. I thank you for the opportunity to get more cheap shares. The volume tells me all I need to know. There is no liquidity left in the stock.

0 · Reply

Market Cap	20.58M
Revenue (ttm)	10,000.00
Net Income (ttm)	-4.05M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	1.20
Profit Margin	-40,500.00%
Debt to Equity Ratio	0.00

Volume	72,600
Avg Vol	73,662
Day's Range	N/A - N/A
Shares Out	14.29M
Stochastic %K	11%
Beta	0.96
Analysts	Strong Sell
Price Target	$10.75